Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
Eligible age
18–60 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study aims to understand the heart and blood sugar health benefits of using an adjunctive therapy to lower high insulin levels in people with type 1 diabetes. The investigators will also look at people with a specific type of diabetes called Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY) and those without diabetes to help interpret the results. The investigators will use a medication that helps the body get rid of sugar, called and SGLT2 inhibitor, with the goal to reduce the body's insulin requirements. The investigators believe this could lead to better heart and blood sugar health, including a better response to insulin and more available nitric oxide, a gas that helps blood vessels function well. The investigators will compare heart and blood sugar health risk factors in participants with type 1 diabetes, participants with Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), and non-diabetic healthy volunteers under two conditions: high insulin levels typical of type 1 diabetes and normal insulin levels typical of the other two groups.
Sponsor: Vanderbilt University Medical Center
You may qualify if…
- ✓ Age: 18-60 years BMI: 18-28 kg/m² Weight: ≥ 50 kg
- ✓ T1DM Participants:
- ✓ Duration of T1DM: 1-30 years HbA1c: 5.7-7.5% Insulin Therapy: Using automated insulin delivery
- ✓ GCK-MODY Participants:
- ✓ HbA1c: 5.7-7.5% Genetic Confirmation: Positive GCK sequencing
- ✓ Control Participants:
- ✓ HbA1c: less than 5.5%
- ✓ \*\* Exclusion Criteria: Severe Hypoglycemia: ≥1 episode in the past 3 months
Where it's recruiting
Nashville
Source: ClinicalTrials.gov · NCT06609356 · last updated 2025-12-23